J&J buys GSK hep. C compound, BI completes trial enrollment

Share this article:
GSK misses on late-stage CV drug
GSK misses on late-stage CV drug

GlaxoSmithKline sold its investigational hepatitis C NS5a replication complex inhibitor to Johnson & Johnson subsidiary Janssen. The J&J unit said in a statement it plans to use Phase II GSK2336805 in interferon-free combinations with its in-house drug simeprevir and its non-nucleoside polymerase inhibitor known as TMC647055. Simeprevir is expected to go before an FDA advisory panel later this month.

This mix-and-match drug approach is common to the space, and competitor Gilead's investigational nucleotide hep. C virus polymerase inhibitor is set to go before an FDA committee one day after J&J's contender gets a thumbs-up or down.

As Boehringer Ingelheim noted in a statement Tuesday, an interferon-free hep. C treatment is an innovation of need, because around 50% of patients cannot take the infusion drugs. This is in addition to patients who are turned off by side effects and the amount of time it takes to complete a course of interferon therapy.

Boehringer's patient-perception walk-through was part of a larger HCV announcement, which was that it had completed enrollment for its all-oral Phase IIa treatment that combines BI's protease inhibitor faldaprevir, its non-nucleoside NS5B polymerase inhibitor deleobuvir, and Presidio Pharmaceutical's pan-genotypic NS5A inhibitor, PPI-668 with and without ribavirin. BI and Presidio's collaboration dates to March, with each company holding on to the rights of their respective compounds. A Phase IIIb faldaprevir-deleobuvir study showed strong efficacy among hepatitis C genotype 1 patients without interferon. Genotype-1 is the most difficult hep. c variation to treat.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...